[go: up one dir, main page]

MX2020014303A - Inhibición de la proteína de union a creb (cbp). - Google Patents

Inhibición de la proteína de union a creb (cbp).

Info

Publication number
MX2020014303A
MX2020014303A MX2020014303A MX2020014303A MX2020014303A MX 2020014303 A MX2020014303 A MX 2020014303A MX 2020014303 A MX2020014303 A MX 2020014303A MX 2020014303 A MX2020014303 A MX 2020014303A MX 2020014303 A MX2020014303 A MX 2020014303A
Authority
MX
Mexico
Prior art keywords
cbp
bromodomains
family
binding protein
creb binding
Prior art date
Application number
MX2020014303A
Other languages
English (en)
Inventor
Torsten Herbertz
Anna Ericsson
Hongbin Li
Steven Mischke
Shawn E R Schiller
Bradford Graves
Angela V West
Jennifer R Downing
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2018/051235 external-priority patent/WO2019055877A1/en
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Publication of MX2020014303A publication Critical patent/MX2020014303A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se refiere a inhibidores de la familia CBP/p300 de bromodominios. Los compuestos pueden ser útiles en el tratamiento de una enfermedad o trastorno asociado con la inhibición de la familia CBP/p300 de bromodominios. Por ejemplo, la descripción se refiere a compuestos y composiciones para la inhibición de la familia de CBP/p300 de bromodominios, métodos para tratar, prevenir o mejorar enfermedades o trastornos asociados con la inhibición de la familia de CBP/p300 de bromodominios y métodos de síntesis de estos compuestos.
MX2020014303A 2018-06-29 2019-06-28 Inhibición de la proteína de union a creb (cbp). MX2020014303A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862692593P 2018-06-29 2018-06-29
PCT/US2018/051235 WO2019055877A1 (en) 2017-09-15 2018-09-14 TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300
PCT/US2018/051214 WO2019055869A1 (en) 2017-09-15 2018-09-14 TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300
US201962819490P 2019-03-15 2019-03-15
PCT/US2019/039936 WO2020006483A1 (en) 2018-06-29 2019-06-28 Inhibiting creb binding protein (cbp)

Publications (1)

Publication Number Publication Date
MX2020014303A true MX2020014303A (es) 2021-03-25

Family

ID=68987627

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020014303A MX2020014303A (es) 2018-06-29 2019-06-28 Inhibición de la proteína de union a creb (cbp).
MX2023013508A MX2023013508A (es) 2018-06-29 2019-06-28 Inhibicion de la proteina de union a creb (cbp).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023013508A MX2023013508A (es) 2018-06-29 2019-06-28 Inhibicion de la proteina de union a creb (cbp).

Country Status (26)

Country Link
US (3) US10870648B2 (es)
EP (1) EP3998266A1 (es)
JP (4) JP6781806B2 (es)
KR (2) KR102805503B1 (es)
CN (2) CN112513038B (es)
AU (2) AU2019295790B2 (es)
BR (1) BR112020026783A2 (es)
CA (1) CA3105099A1 (es)
CY (1) CY1124762T1 (es)
DK (1) DK3587418T3 (es)
ES (1) ES2900105T3 (es)
HR (1) HRP20211698T1 (es)
HU (1) HUE056885T2 (es)
IL (2) IL313466B1 (es)
LT (1) LT3587418T (es)
MA (1) MA50675B1 (es)
MX (2) MX2020014303A (es)
PL (1) PL3587418T3 (es)
PT (1) PT3587418T (es)
RS (1) RS62732B1 (es)
SA (1) SA520420909B1 (es)
SG (1) SG11202012767UA (es)
SI (1) SI3587418T1 (es)
SM (1) SMT202100636T1 (es)
WO (1) WO2020006483A1 (es)
ZA (1) ZA202100509B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020014303A (es) * 2018-06-29 2021-03-25 Forma Therapeutics Inc Inhibición de la proteína de union a creb (cbp).
AU2020241709A1 (en) * 2019-03-15 2021-09-23 Forma Therapeutics, Inc. Compositions and methods for treating androgen receptor positive forms of cancer
TW202102494A (zh) 2019-03-15 2021-01-16 美商弗瑪治療公司 抑制環amp-反應元件-結合蛋白(creb)
US20230233558A1 (en) 2020-06-25 2023-07-27 Tolremo Therapeutics Ag Combination of a cbp/p300 bromodomain inhibitor and a kras inhibitor for the treatment of cancer
CA3183982A1 (en) 2020-06-25 2021-12-30 Stefanie Fluckiger-Mangual A combination of a cbp/p300 bromodomain inhibitor and an egfr inhibitor for use in treating egfr-mutant nsclc
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en) * 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404207A (en) 1981-11-06 1983-09-13 Riker Laboratories, Inc. Antimicrobial 8-substituted benzo [IJ]quinolizines
US5138089A (en) * 1986-06-27 1992-08-11 The Procter & Gamble Company Chromophores, sunscreen compositions and methods for preventing sunburn
AU1868195A (en) 1994-01-28 1995-08-15 Cell Therapeutics, Inc. Cell signaling inhibitors
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US6455564B1 (en) 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
US7101869B2 (en) 1999-11-30 2006-09-05 Pfizer Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
US7345051B2 (en) 2000-01-31 2008-03-18 Genaera Corporation Mucin synthesis inhibitors
DE60134886D1 (de) 2000-11-20 2008-08-28 Merck Patent Gmbh Chirale photoisomerisierbare verbindungen
CA2463136A1 (en) 2001-10-17 2003-04-24 Raymond Andersen Ship 1 modulators
EP1460067A4 (en) 2001-11-26 2005-12-07 Takeda Pharmaceutical BICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE
HUP0203976A3 (en) 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
TWI322012B (en) 2002-12-20 2010-03-21 Organon Nv Tetrahydroquinoline derivatives
IN2003CH00929A (es) 2003-11-13 2008-10-06
US20080188527A1 (en) 2003-12-23 2008-08-07 Cashman John R Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer
CA2562244A1 (en) 2004-04-07 2005-10-27 Takeda Pharmaceutical Company Limited Cyclic compounds
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
WO2007120339A1 (en) 2005-12-19 2007-10-25 Genentech, Inc. Pyrimidine kinase inhibitors
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
US20080075692A1 (en) 2006-05-09 2008-03-27 Perrine Susan P Methods for treating blood disorders
EP1878724A1 (en) 2006-07-15 2008-01-16 sanofi-aventis A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles
CA2574531C (en) 2007-01-19 2016-10-25 The University Of British Columbia Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity
IN2014MN02330A (es) 2007-06-21 2015-08-14 Wistar Inst
MX2009013753A (es) 2007-06-26 2010-01-26 Sanofi Aventis Una sintesis regioselectiva catalizada por cobre de bencimidazoles y azabencimidazoles.
WO2009001817A1 (ja) 2007-06-27 2008-12-31 Taisho Pharmaceutical Co., Ltd. １１β－ＨＳＤ１阻害活性を有する化合物
TW200930369A (en) 2007-11-15 2009-07-16 Astrazeneca Ab Bis-(sulfonylamino) derivatives in therapy
AR072008A1 (es) 2008-06-13 2010-07-28 Merck & Co Inc Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38
EP3289876B1 (en) 2008-06-16 2022-07-20 University of Tennessee Research Foundation Compounds for treatment of cancer
JP5586585B2 (ja) * 2009-03-27 2014-09-10 興和株式会社 縮合ピペリジン化合物及びこれを含有する医薬
WO2010118208A1 (en) 2009-04-09 2010-10-14 Exelixis, Inc. Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer
AU2010237633B2 (en) 2009-04-15 2015-09-17 Jw Pharmaceutical Corporation Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof
WO2010138490A1 (en) 2009-05-26 2010-12-02 Exelixis, Inc. Benzoxazepines as inhibitors of mtor and methods of their use and manufacture
MX2011012584A (es) 2009-05-26 2012-02-21 Exelixis Inc Benzoxazepinas como inhibidores de pi3k/m tor, metodos para su uso y fabricación.
US9005670B2 (en) 2010-01-05 2015-04-14 The Johns Hopkins University Use of histone acetyltransferase inhibitors as novel anti-cancer therapies
RU2581367C2 (ru) 2010-03-01 2016-04-20 Джи Ти Икс, ИНК. Соединения для лечения рака
CN103038229B (zh) * 2010-05-26 2016-05-11 桑诺维恩药品公司 杂芳基化合物及其使用方法
WO2012019093A1 (en) 2010-08-05 2012-02-09 Human Biomolecular Research Institute Synthetic compounds and methods to decrease nicotine self-administration
WO2012080727A2 (en) 2010-12-14 2012-06-21 Electrophoretics Limited Casein kinase 1delta (ck1delta) inhibitors
US8765978B2 (en) 2010-12-16 2014-07-01 Transitions Optical, Inc. Method of making indeno-fused naphthol materials
EP2678050B1 (en) 2011-02-24 2020-10-14 Emory University Noggin blocking compositions for ossification and methods related thereto
TWI478908B (zh) 2011-07-01 2015-04-01 Gilead Sciences Inc 作為離子通道調節劑之稠合雜環化合物
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
WO2013148114A1 (en) 2012-03-30 2013-10-03 University Of Florida Research Foundation, Inc. P300/cbp inhibitors and methods of use
US9211333B2 (en) 2012-06-05 2015-12-15 Hong Kong Baptist University Anti-cancer agents synthesized based on miliusane compounds
IN2015DN02008A (es) 2012-09-21 2015-08-14 Advinus Therapeutics Ltd
RU2543485C2 (ru) 2013-02-26 2015-03-10 Андрей Александрович Иващенко Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
BR112015031073B1 (pt) 2013-06-21 2022-11-29 Zenith Epigenetics Ltd Compostos inibidores bicíclicos de bromodomínio e composição farmacêutica contendo os referidos compostos
US9662311B2 (en) 2013-06-21 2017-05-30 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
HK1224140A1 (zh) 2013-07-25 2017-08-18 达纳-法伯癌症研究所股份有限公司 轉錄因子抑制劑及其用途
DE102013215912B3 (de) 2013-08-12 2015-02-26 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Farbneutral beschichteter kupferhaltiger Gegenstand, Verfahren zu dessen Herstellung sowie Verwendung einer entsprechenden farbneutralen Beschichtung
AR098414A1 (es) 2013-11-14 2016-05-26 Bristol Myers Squibb Co PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e
SI3071203T1 (sl) * 2013-11-18 2021-07-30 Forma Therapeutics, Inc. Sestavki tetrahidrokinolina, kot zaviralci BET bromodomene
RU2720237C2 (ru) 2013-11-18 2020-04-28 Форма Терапеутикс, Инк. Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
EP3193866A1 (en) 2014-09-19 2017-07-26 Genentech, Inc. Use of cbp/ep300 and bet inhibitors for treatment of cancer
JP6771464B2 (ja) * 2014-11-27 2020-10-21 ジェネンテック， インコーポレイテッド Ｃｂｐおよび／またはｅｐ３００インヒビターとしての、４，５，６，７−テトラヒドロ−１ｈ−ピラゾロ［４，３−ｃ］ピリジン−３−アミン化合物
JP6854776B2 (ja) 2015-01-08 2021-04-07 インぺティス バイオサイエンス リミテッド 二環式化合物、その組成物および医薬用途
WO2016128908A1 (en) 2015-02-12 2016-08-18 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
EP3454945B1 (en) 2016-05-12 2022-01-19 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
MA45122A (fr) 2016-05-24 2019-04-10 Constellation Pharmaceuticals Inc Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer
GB201617630D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
GB201617627D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
TW202332436A (zh) * 2017-04-18 2023-08-16 美商塞爾基因定量細胞研究公司 治療用化合物
AU2018334272B2 (en) * 2017-09-15 2023-06-15 Forma Therapeutics, Inc. Tetrahydro-imidazo quinoline compositions as CBP/p300 inhibitors
MX2020014303A (es) * 2018-06-29 2021-03-25 Forma Therapeutics Inc Inhibición de la proteína de union a creb (cbp).

Also Published As

Publication number Publication date
KR102805503B1 (ko) 2025-05-09
SMT202100636T1 (it) 2022-01-10
DK3587418T3 (da) 2021-10-11
ES2900105T3 (es) 2022-03-15
PT3587418T (pt) 2021-12-02
KR20210025631A (ko) 2021-03-09
CY1124762T1 (el) 2022-07-22
JP2020128426A (ja) 2020-08-27
KR20250067962A (ko) 2025-05-15
PL3587418T3 (pl) 2022-02-21
IL313466A (en) 2024-08-01
JP2021042255A (ja) 2021-03-18
CN116178369A (zh) 2023-05-30
IL313466B1 (en) 2025-07-01
HUE056885T2 (hu) 2022-03-28
JP2020002135A (ja) 2020-01-09
CA3105099A1 (en) 2020-01-02
ZA202100509B (en) 2022-12-21
LT3587418T (lt) 2021-11-25
BR112020026783A2 (pt) 2021-03-30
US20220162207A1 (en) 2022-05-26
AU2019295790A1 (en) 2021-01-28
AU2023226653A1 (en) 2023-09-21
US11254674B2 (en) 2022-02-22
SI3587418T1 (sl) 2022-03-31
JP6781806B2 (ja) 2020-11-04
AU2019295790B2 (en) 2023-07-13
MA50675A (fr) 2021-04-07
HRP20211698T1 (hr) 2022-02-18
MX2023013508A (es) 2023-12-13
IL279734A (en) 2021-03-01
CN112513038A (zh) 2021-03-16
US20200299295A1 (en) 2020-09-24
CN112513038B (zh) 2023-01-10
SA520420909B1 (ar) 2024-11-12
IL279734B2 (en) 2024-11-01
JP2025094157A (ja) 2025-06-24
MA50675B1 (fr) 2021-09-30
RS62732B1 (sr) 2022-01-31
EP3998266A1 (en) 2022-05-18
US20200002332A1 (en) 2020-01-02
IL279734B1 (en) 2024-07-01
US10870648B2 (en) 2020-12-22
SG11202012767UA (en) 2021-01-28
JP7017801B2 (ja) 2022-02-09
WO2020006483A1 (en) 2020-01-02

Similar Documents

Publication Publication Date Title
MX2020014303A (es) Inhibición de la proteína de union a creb (cbp).
ECSP21075909A (es) Inhibidores de la proteína tirosina fosfatasa y métodos para usarlos
PH12022552739A1 (en) Fused tricyclic kras inhibitors
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
MX2024000357A (es) Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras).
MX2024004318A (es) Inhibidores de proteina tirosina fosfatasa y sus metodos de uso.
MX2021002805A (es) Terapias de combinacion.
MX2015013948A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
CO2023010023A2 (es) Inhibidores de cdk2 y métodos de uso de los mismos
PH12021551304A1 (en) Tyrosine kinase inhibitors, compositions and methods there of
BR112022001270A2 (pt) Compostos inibidores
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
MX375924B (es) Moduladores de proteinas del choque termico 70 (hsp70) y metodos para fabricar y usar el mismo.
EA201990508A1 (ru) ИНГИБИРОВАНИЕ АКТИВНОСТИ Olig2
EA202190902A1 (ru) Ингибирование синтазы жирных кислот (fasn)
EA202092446A1 (ru) ТИАЗОЛ- ИЛИ ТИАДИАЗОЛЗАМЕЩЕННЫЕ АРИЛЬНЫЕ И ГЕТЕРОАРИЛЬНЫЕ ПРОИЗВОДНЫЕ КАК ИНГИБИТОРЫ Vps34
BR112021016921A2 (pt) Inibição de proteína de ligação a elemento responsivo a amp cíclico (creb)
EA202190112A1 (ru) Ингибирование creb-связывающего белка (cbp)
EA201992793A1 (ru) Ингибиторы протеинкиназ
MX2022003164A (es) Composiciones para usar para la inhibicion de cinasa src y el tratamiento y la prevencion de trastornos asociados.
AR129088A1 (es) INHIBIDORES DE PI3Ka
EA201990393A1 (ru) Композиции и способы для ингибирования masp-3, применяемые в целях лечения различных заболеваний и расстройств
EA201891687A1 (ru) Новые замещённые производные цианиндолина в качестве nik- ингибиторов